Polyrizon Enrolls First Patient in NASARIX U.S. Study
RAANANA, Israel — September 22, 2026 Polyrizon Ltd. announced enrollment of the first patient in its U.S. clinical study...
Clinical Study
Advertisement
Pulse Biosciences Completes PRECISE-BTN Enrollment
HAYWARD, Calif. — September 15, 2026 Pulse Biosciences, Inc. announced completion of enrollment in the PRECISE-BTN clinical study evaluating...
Nyxoah Begins U.S. BREATHE Study With First Genio Implant
Mont-Saint-Guibert, Belgium — September 7, 2026 Nyxoah announced that the first patient has been implanted in BREATHE, its U.S....
Harrow Reports 58% Reduction in Patient-Reported Discomfort with IHEEZO®
NASHVILLE, Tennessee, August 20, 2026 Harrow, Inc. announced positive results from a prospective, randomized contralateral-eye study evaluating IHEEZO® (chloroprocaine...
Lilly’s Olomorasib Earns FDA Breakthrough Therapy Designation
Indianapolis, August 3, 2026 Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted...
Advertisements
Fresenius Kabi Gains FDA Approval for Rituximab Biosimilar
Bad Homburg, Germany, August 3, 2026 Fresenius Kabi, an operating company of Fresenius, announced that the U.S. Food and...
Invenio Imaging Completes Enrollment in AI Lung Cancer Study
San Jose, California, August 3, 2026 Invenio Imaging announced the completion of patient enrollment in the ON-SITE pivotal study,...
Natera Reports Signatera Superior to AMERK in MCC Monitoring
AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...
Harrow Highlights New IHEEZO and BYOOVIZ Clinical Evidence at ASRS 2026
NASHVILLE, Tenn., July 20, 2026 Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,...
MindMaze Supports Stroke Recovery Combination Therapy Study
GENEVA, Switzerland, July 9, 2026 MindMaze Therapeutics Holding SA has announced its support for a University of Pittsburgh clinical...
Advertisement
